We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+33.1%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$195M
Cap. Flow
+$52.3M
Cap. Flow %
6.9%
Top 10 Hldgs %
45.66%
Holding
77
New
20
Increased
20
Reduced
12
Closed
17

Top Buys

1
SRPT icon
Sarepta Therapeutics
SRPT
+$21.6M
2
WINT
Windtree Therapeutics Inc
WINT
+$13.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$12.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$10.9M
5
DVAX
Dynavax Technologies
DVAX
+$10.6M

Top Sells

1
NTUS
Natus Medical Inc
NTUS
+$29.1M
2
ALKS icon
Alkermes
ALKS
+$15.1M
3
IART icon
Integra LifeSciences
IART
+$8.91M
4
SPNC
Spectranetics Corp
SPNC
+$8.33M
5
NUVA
NuVasive, Inc.
NUVA
+$7.35M

Sector Composition

1 Healthcare 76.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASRT
1
DELISTED
Assertio
ASRT
$50.2M 6.62%
79,080
-14,620
-16% -$7.15M
LCI
2
DELISTED
Lannett Company, Inc.
LCI
$44.4M 5.85%
334,986
+7,846
+2% +$830K
ANGO icon
3
AngioDynamics
ANGO
$558M
$42.8M 5.65%
2,497,049
-329,602
-12% -$5.07M
TEVA icon
4
Teva Pharmaceuticals
TEVA
$37.3B
$33.7M 4.45%
841,736
+200,000
+31% +$7.88M
NVDQ
5
DELISTED
Novadaq Technologies Inc.
NVDQ
$32.5M 4.28%
1,969,634
+282,544
+17% +$4.68M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$32.4M 4.28%
4,257,469
+2,377,469
+126% +$12.8M
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
$30.3M 4%
3,767,911
– –
TTPH
8
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$29.7M 3.91%
109,666
+20,000
+22% +$4.77M
ANAC
9
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$25.5M 3.36%
1,517,231
-220,438
-13% -$3.05M
EBS icon
10
Emergent Biosolutions
EBS
$394M
$24.7M 3.26%
1,074,048
-200
-0% -$4.17K
NTUS
11
DELISTED
Natus Medical Inc
NTUS
$22.8M 3.01%
1,014,116
-1,506,876
-60% -$29.1M
PGNX
12
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$21.3M 2.81%
4,000,000
+520,652
+15% +$2.29M
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
$20.2M 2.67%
734,410
+485,954
+196% +$10.9M
AUXL
14
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$19.9M 2.63%
961,100
+150,000
+18% +$2.83M
IPXL
15
DELISTED
Impax Laboratories, Inc.
IPXL
$18.5M 2.43%
733,929
-188,614
-20% -$4.21M
WINT
16
DELISTED
Windtree Therapeutics Inc
WINT
$18.1M 2.39%
576,143
+421,429
+272% +$13.2M
ACGN
17
DELISTED
Aceragen Inc
ACGN
$16.4M 2.17%
26,129
-7,176
-22% -$2.39M
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.82B
$14.8M 1.95%
+726,655
New +$21.6M
CEMP
19
DELISTED
Cempra, Inc.
CEMP
$14.4M 1.9%
1,164,547
-226,810
-16% -$2.74M
DVAX
20
DELISTED
Dynavax Technologies
DVAX
$14.2M 1.87%
+725,000
New +$10.6M
RIGL icon
21
Rigel Pharmaceuticals
RIGL
$750M
$14.1M 1.86%
495,512
+138,930
+39% +$4.08M
INFI
22
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$13.8M 1.81%
996,000
+706,000
+243% +$9.97M
BDSI
23
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$13.1M 1.73%
2,222,054
+100,000
+5% +$515K
NPSP
24
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$12.1M 1.6%
400,000
-51,597
-11% -$1.42M
TXMD icon
25
TherapeuticsMD
TXMD
$23.8M
$11.1M 1.46%
42,563
– –
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2013 Portfolio in Review

As of Q4 2013, Broadfin Capital held 77 positions worth $758M, up 35% from $563M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Broadfin Capital deployed $52.3M of net new capital in Q4 2013, opening 20 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 726,655 shares worth $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 78% a quarter earlier.

On the sell side, the largest reduction was Natus Medical Inc, an estimated $29.1M trimmed.

  • Broadfin Capital's largest Q4 2013 buy was Sarepta Therapeutics: 726,655 shares worth $14.8M.
  • Broadfin Capital added most to Windtree Therapeutics Inc in Q4 2013, an estimated $13.2M increase.
  • Broadfin Capital's biggest Q4 2013 reduction was Natus Medical Inc, cutting an estimated $29.1M.
  • Broadfin Capital fully exited Alkermes in Q4 2013, selling an estimated $15.1M.
  • Broadfin Capital's ten largest holdings make up 46% of its $758M portfolio in Q4 2013.
  • Broadfin Capital opened 20 new positions and closed 17 in Q4 2013.
  • Broadfin Capital's portfolio value rose 35% quarter-over-quarter to $758M.

Based on Broadfin Capital's 13F filing for Q4 2013, filed 14 Feb 2014.